Sanofi stock price

Sanofi latest news:


  • 02/15/2018 00:48:19

    Oxford BioMedica wins second $100 mln gene therapy contract

    LONDON, Feb 15 (Reuters) - Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

  • 02/07/2018 01:38:39

    UPDATE 2-Drugmaker Sanofi sees return to profit growth this year

    * Outlook disappoints, shares down 2 pct (Adds share price, comments, details)

  • 01/29/2018 14:40:14

    Sanofi and Verizon skid while Dr. Pepper Snapple leaps

    Sanofi and Verizon Communications stumble while Dr. Pepper Snapple Group and Lockheed Martin climb

  • 01/29/2018 14:39:48

    Sanofi and Verizon skid while Dr. Pepper Snapple leaps

    Stocks that moved substantially or traded heavily on Monday: Dr. Pepper Snapple Group Inc., up $21.42 to $117.07

  • 01/29/2018 10:14:48

    Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

    PARIS/LONDON (Reuters) - French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.

  • 01/29/2018 10:08:39

    UPDATE 2-Chipmakers, Sanofi deal dominate European share trading

    * Bond yield rise hits income stocks, utilities (Adds prices, details)

  • 01/29/2018 00:38:37

    Healthcare group Sanofi to buy Ablynx for 3.9 billion euros

    Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros, the companies said on Monday, marking the French drug maker's second major takeover deal this month following its acquisition of Bioverativ (BIVV). The companies said Sanofi would pay 45 euros per share in cash for Ablynx, a premium of 21.2 percent over the Belgian firm's closing stock price on Friday.

  • 01/26/2018 18:54:54

    U.S. SEC files suit over possible insider trading on Bioverativ

    The U.S. Securities and Exchange Commission filed an insider trading lawsuit on Friday against "unknown traders" who it said engaged in "highly suspicious trading" just ahead of the announcement that hemophilia specialist Bioverativ Inc (BIVV) had agreed to be acquired by France's Sanofi in an $11.6 billion deal.

  • 01/22/2018 09:03:35

    WRAPUP 2-Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    * Large drugmakers scour for products from smaller biotechs (Adds detail on gains in other biotech shares)

  • 01/22/2018 08:57:16

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    LONDON, Jan 22 (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets.

  • 01/22/2018 08:25:29

    Sanofi Moves to Acquire Bioverativ


  • 01/22/2018 07:32:45

    U.S. stocks open slightly lower in first trading day of government shutdown

    U.S. stocks fell modestly at the open on Monday, as investors found few reasons to keep pushing shares higher following a push to repeated records, and as the government shutdown provided another element of uncertainty to markets. The Dow Jones Industrial Average fell 72 points, or 0.2%, to 26,011. The S&P 500 declined 1 point to 2,809, a drop of less than 0.1%. The Nasdaq Composite Index was unchanged at 7,336. Both the S&P and the Nasdaq are coming off closing records, while the Dow is close to its own peak. While government shutdowns have historically not been big selling catalysts, uncertainty over when the government would reopened appeared to dampen buying enthusiasm. The Senate was expected to hold a procedural vote at noon Eastern Time on a measure that would keep the government funded through Feb. 8, but it wasn't clear if it would have enough support to advance. In company news, Juno Therapeutics Inc. jumped 27% after Celgene Corp. agreed to buy the company for $9 billion. Bioverativ Inc. soared 63% after Sanofi SA said it would buy it for $12 billion.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/22/2018 00:48:18

    Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion

    PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, in a deal which it said would boost earnings and strengthen its presence in treatments for rare diseases.

  • 01/21/2018 23:58:28

    Healthcare group Sanofi agrees to buy U.S. peer Bioverativ for $11.6 billion

    PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatments for rare diseases.

  • 01/21/2018 23:28:00

    Sanofi confirms deal to buy Bioverativ for $11.6 billion

    French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $11.6 billion.

  • 01/21/2018 19:22:12

    Sanofi set to buy Bioverativ for more than $11.5 billion: WSJ

    (Reuters) - Sanofi SA is close to a deal to take over U.S. drug maker Bioverativ Inc for more than $11.5 billion, the Wall Street Journal reported, citing people familiar with the matter.

  • 01/08/2018 00:23:34

    BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

    * AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

  • 01/07/2018 23:58:24

    Sanofi to market new hemophilia drug in deal with Alnylam

    PARIS, Jan 8 (Reuters) - French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

  • 12/12/2017 23:04:51

    BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous ...

    Regeneron Pharmaceuticals Inc(REGN): * REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. * REGENERON PHARMACEUTICALS INC SAYS SAFETY PROFILE IN STUDY WAS GENERALLY CONSISTENT WITH APPROVED ANTI-PD-1 AGENTS.

  • 12/11/2017 12:04:25

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's (LLY) fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes.

  • 12/11/2017 12:04:06

    UPDATE 1-FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

  • 12/11/2017 11:13:52

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

  • 12/04/2017 18:10:17

    Trial results of Zika vaccine Sanofi dropped show promise

    A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of those taking part in an early-stage clinical trial, U.S. researchers reported on Monday. The results, published in the journal Lancet, offer a first glimpse at the vaccine's performance in people, and suggest it might have had a promising future.

  • 12/04/2017 12:58:08

    Trouble mounts for Sanofi dengue vaccine over safety concerns

    The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases.

  • 12/04/2017 07:52:19

    Brazil recommends restrictions on Sanofi dengue vaccine

    The Brazilian government said on Monday it has suggested restrictions on the use of a dengue vaccine that has been suspended elsewhere after French drug company Sanofi SA said it could worsen the disease in some cases.

  • 12/03/2017 23:25:45

    Philippines orders probe into vaccine, Sanofi says no deaths reported

    MANILA (Reuters) - The Philippines ordered a probe on Monday into the immunization of more than 730,000 children with a dengue vaccine that has since been suspended, while French drug company Sanofi said no deaths had been reported as a result of the program.

  • 12/01/2017 15:37:25

    UPDATE 1-Sanofi ends development of C. difficile vaccine

    Dec 1 (Reuters) - Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success.

  • 12/01/2017 14:43:26

    Sanofi ends development of C. difficile vaccine

    Dec 1 (Reuters) - Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success.

  • 12/01/2017 09:23:19

    BioTelemetry's (BEAT) Telcare Unit Collaborates With Onduo

    BioTelemetry Inc s BEAT Telcare division recently signed a partnership agreement with Onduo a joint venture by Verily an Alphabet company and 160 Sanofi Per the agreement Telcare will act as an authorized provider of remote blood glucose systems along with the resulting data

  • More trends:

    Sapiens International Corporation N.V.SPNS | Sarepta Therapeutics, Inc.SRPT | SB Financial Group, Inc.SBFG | SB Financial Group, Inc.SBFGP | SBA Communications CorporationSBAC | ScanSource, Inc.SCSC | Schmitt Industries, Inc.SMIT | Schnitzer Steel Industries, Inc.SCHN | Scholastic CorporationSCHL | SciClone Pharmaceuticals, Inc.SCLN |